LTFS
IBB icon

Ladenburg Thalmann Financial Services’s iShares Biotechnology ETF IBB Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$7.53M Sell
97,867
-21,653
-18% -$2.42M 0.05% 368
2019
Q3 		$11.9M Buy
119,520
+53,975
+82% +$5.65M 0.08% 237
2019
Q2 		$7.15M Sell
65,545
-3,897
-6% -$415K 0.05% 354
2019
Q1 		$7.76M Sell
69,442
-2,154
-3% -$236K 0.06% 312
2018
Q4 		$6.91M Sell
71,596
-8,791
-11% -$933K 0.06% 277
2018
Q3 		$9.8M Buy
80,387
+4,427
+6% +$521K 0.08% 212
2018
Q2 		$8M Hold
75,960
– – 0.07% 246
2018
Q1 		$8M Buy
75,960
+5,845
+8% +$648K 0.07% 246
2017
Q4 		$7.49M Sell
70,115
-28,594
-29% -$3.06M 0.07% 264
2017
Q3 		$11M Sell
98,709
-3,006
-3% -$321K 0.12% 167
2017
Q2 		$10.5M Buy
101,715
+9,321
+10% +$918K 0.12% 160
2017
Q1 		$9.02M Buy
92,394
+14,667
+19% +$1.4M 0.11% 167
2016
Q4 		$6.88M Sell
77,727
-17,916
-19% -$1.63M 0.1% 197
2016
Q3 		$9.23M Buy
95,643
+9,753
+11% +$928K 0.14% 150
2016
Q2 		$7.37M Buy
85,890
+19,701
+30% +$1.77M 0.12% 175
2016
Q1 		$5.75M Sell
66,189
-23,373
-26% -$2.09M 0.1% 197
2015
Q4 		$10.1M Sell
89,562
-25,911
-22% -$2.81M 0.19% 122
2015
Q3 		$11.7M Sell
115,473
-17,250
-13% -$2.07M 0.24% 101
2015
Q2 		$16.3M Sell
132,723
-2,505
-2% -$300K 0.3% 80
2015
Q1 		$15.5M Buy
135,228
+24,966
+23% +$2.75M 0.3% 74
2014
Q4 		$11.1M Buy
110,262
+51,873
+89% +$5.04M 0.25% 91
2014
Q3 		$5.33M Buy
58,389
+17,952
+44% +$1.58M 0.15% 136
2014
Q2 		$3.46M Sell
40,437
-1,290
-3% -$102K 0.09% 179
2014
Q1 		$3.29M Buy
41,727
+4,209
+11% +$351K 0.1% 162
2013
Q4 		$2.84M Buy
37,518
+744
+2% +$52.8K 0.09% 184
2013
Q3 		$2.57M Buy
36,774
+5,646
+18% +$370K 0.09% 183
2013
Q2 		$1.81M Buy
+31,128
New +$1.8M 0.06% 237

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Ladenburg Thalmann Financial Services's IBB Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its iShares Biotechnology ETF (IBB) stake by 18% in Q4 2019, selling an estimated $2.42M and leaving 97,867 shares worth $7.53M. The position accounts for 0.05% of the portfolio, ranked #368.

Ladenburg Thalmann Financial Services first reported a position in IBB in Q2 2013 and has held it in 27 quarters since. The position peaked at $16.3M in Q2 2015. 710 funds tracked by Wall St. Rank hold IBB as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 97,867 shares of iShares Biotechnology ETF worth $7.53M as of Q4 2019.
  • Ladenburg Thalmann Financial Services sold 21,653 iShares Biotechnology ETF shares in Q4 2019, an estimated $2.42M.
  • iShares Biotechnology ETF made up 0.05% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #368 holding.
  • Ladenburg Thalmann Financial Services first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 27 quarters since.
  • Ladenburg Thalmann Financial Services's iShares Biotechnology ETF position peaked at $16.3M in Q2 2015.
  • 710 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.